Frampton R, Snaith JR, Hocking S, Holmes-Walker J, et al. Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial. Diabet Med 2024 Jun 9:e15377. doi: 10.1111/dme.15377.
PMID: 38853340